Response to trabectedin treatment in a highly pretreated patient with an advanced meningeal hemangiopericytoma

Anti-Cancer Drugs

Volumn 21, Issue 8, 2010, Pages 795-798

  Martinez Trufero, Javier ^a   Alfaro, Jorge ^a   Felipo, Francesc ^a   Alvarez, Maria ^a   Madani, Julia ^a   Cebollero, Ana ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

hemangiopericytoma; rare tumor; solitary fibrous tumor; trabectedin

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; DACARBAZINE; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; SUNITINIB; TEMOZOLOMIDE; TRABECTEDIN;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; HEMANGIOPERICYTOMA; HUMAN; INTRACRANIAL HYPERTENSION; LIVER METASTASIS; LUNG METASTASIS; LUNG NODULE; MALE; MENINGIOMA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIOXOLES; HEMANGIOPERICYTOMA; HUMANS; MALE; MENINGEAL NEOPLASMS; NEOPLASM STAGING; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME;

EID: 77955228557     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833d19f0     Document Type: Article

References (29)

1. Guthrie BL, Ebersold MJ, Scheithauer BW, Shaw EG. Meningeal hemangiopericytoma: histopathological features, treatment, and long-term follow-up of 44 cases. Neurosurgery 1989; 25:514-522.
2. Goellner JR, Laws ER Jr, Soule EH, Okazaki H. Hemangiopericytoma of the meninges. Mayo Clinic experience. Am J Clin Pathol 1978; 70:375-380.
3. Mena H, Ribas JL, Pezeshkpour GH, Cowan DN, Parisi JE. Hemangiopericytoma of the central nervous system: a review of 94 cases. Hum Pathol 1991; 22:84-91.
4. Soyuer S, Chang EL, Selek U, McCutcheon IE, Maor MH. Intracranial meningeal hemangiopericytoma: the role of radiotherapy: report of 29 cases and review of the literature. Cancer 2004; 100:1491-1497.
5. Galanis E, Buckner JC, Scheithauer BW, Kimmel DW, Schomberg PJ, Piepgras DG. Management of recurrent meningeal hemangiopericytoma. Cancer 1998; 82:1915-1 920.
6. Park MS, Araujo DM. New insights into the hemangiopericytoma/solitary fibrous tumor spectrum of tumors. Curr Opin Oncol 2009; 21:327-331.
7. Kim JH, Jung HW, Kim YS, Kim CJ, Hwang SK, Paek SH, et al. Meningeal hemangiopericytomas: long-term outcome and biological behavior. Surg Neurol 2003; 59:47-53.
8. Combs SE, Thilmann C, Debus J, Schulz-Ertner D. Precision radiotherapy for hemangiopericytomas of the central nervous system. Cancer 2005; 104:2457-2465.
9. Kirn DH, Kramer A. Long-term freedom from disease progression with interferon-a therapy in two patients with malignant hemangiopericytoma. J Natl Cancer Inst 1996; 88:764-765.
10. Lackner H, Urban C, Dornbusch HJ, Schwinger W, Kerbl R, Sovinz P. Interferon a-2a in recurrent metastatic hemangiopericytoma. Med Pediatr Oncol 2003; 40:192-194.
11. Chamberlain MC, Glantz MJ. Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma. Neurosurgery 2008; 63:720-726.
12. Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, et al. Combination therapy with temozolomide and bevacizumab in the treatment of hemangiopericytoma/malignant solitary fibrous tumor. J Clin Oncol 2008; 26 (May 20 Suppl ):10512.
13. Ryan CW, von Mehren M, Rankin CJ, Goldblum JR, Demetri GD, Bramwell VH, Borden EC. Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505. J Clin Oncol 2008; 26 (May 20 Suppl):10532.
14. Domont J, Massard C, Lassau N, Armand JP, Le Cesne A, Soria JC. Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma/solitary fibrous tumour. Invest New Drugs 2010; 28:199-202.
15. Mulamalla K, Truskinovsky AM, Dudek AZ. Rare case of hemangiopericytoma responds to sunitinib. Transl Res 2008; 151:129-133.
16. Garcia Del Muro X, Fra J, Lopez Pousa A, Maurel J, Martin J, Martinez Trufero J, et al. Randomized phase II study of dacarbazine plus gemcitabine versus DTIC alone in patients with advanced soft tissue sarcoma: a Spanish Group for Research on Sarcomas (GEIS) study. J Clin Oncol 2009; 27 (Suppl):10529.
17. Spitz FR, Bouvet M, Pisters PW, Pollock RE, Feig BW. Hemangiopericytoma: a 20-year single-institution experience. Ann Surg Oncol 1998; 5:350-355.
18. Yadav SK, Haider K, Yadav AS, Sami A, Mirchandani D, Ahmad I, et al. Long term outcomes in malignant hemangiopericytoma. J Clin Oncol 2005 ASCO Annual Meeting Proceedings. Vol. 23, No. 16S, Part I of II (June 1 Suppl), 2005: 9072.
19. Wong PP, Yagoda A. Chemotherapy of malignant hemangiopericytoma. Cancer 1978; 41:1256-1260.
20. Beadle GF, Hillcoat BL. Treatment of advanced malignant hemangiopericytoma with combination adriamycin and DTIC: a report of four cases. J Surg Oncol 1983; 22:167-1 70.
21. Park MS, Lazar AJ, Trent JC, Conrad CA, Ludwig JA, Wang W, et al. Combination therapy with temozolomide and bevacizumab in the treatment of hemangiopericytoma/solitary fibrous tumor: an updated analysis [abstract #35064]. In: 14th Connective Tissue Oncologic Society Annual Meeting; 13-15 November 2008b; London.
22. Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004; 22:1480-1490.
23. Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005; 23:576-584.
24. Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004; 22:890-899.
25. Schoffski P, Dumez H, Wolter P, Stefan C, Wozniak A, Jimeno J, Van Oosterom AT. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. Expert Opin Pharmacother 2008; 9:1609-1618.
26. Dankwah-Quansah MA, Gutin P, Bilsky M, Huse J, Rosenblum M, Abrey LE, et al. Patterns of care and outcomes in patients with intracranial hemangiopericytomas: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience. J Clin Oncol 2009; 27 (May 20 Suppl):e13011.
27. Hollebecque A, Adenis A, Taieb S, Lebedinsky C, Penel N. Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients. Invest New Drugs 2010; 28:529-530.
28. Carter NJ, Keam SJ. Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer. Drugs 2010; 70:355-376.
29. Hing J, Perez-Ruixo JJ, Stuyckens K, Soto-Matos A, Lopez-Lazaro L, Zannikos P. Mechanism-based pharmacokinetic/pharmacodynamic meta- analysis of trabectedin (ET-743, Yondelis) induced neutropenia. Clin Pharmacol Ther 2008; 83:130-143.